ASND · Ascendis Pharma A/S
$245.15
+0.73% last session
End-of-day data · close of 2026-10-26
Market cap
$16B
Enterprise value
$16B
Trailing P/E
18.3
Forward P/E
25.3
Dividend yield
0.0%
Beta
—
Avg volume
1M
Employees
1K
Daily Change %
0.73%
5 Days Change
7.88%
10 Days Change
8.86%
30 Days Change
8.90%
60 Days Change
-3.56%
Month to Day Change
6.90%
Year to Day Change
13.95%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — ASND
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-26
Latest call per bank · past 12 months
Citigroup
Buy$330
+35.6% vs priceMorgan Stanley
Overweight$273
+12.2% vs priceBank of America
Buy$304
+24.9% vs priceJefferies
Buy$330
+35.6% vs priceRBC Capital
Outperform$290
+19.2% vs priceBarclays
Overweight$329
+35.2% vs priceWells Fargo
Overweight$326
+34.0% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-26 | Citigroup | Maintains | Buy | $360 → $330 |
| 2026-09-25 | Cantor Fitzgerald | Reiterates | Overweight | $300 |
| 2026-09-15 | Raymond James | Downgrade | Strong Buy → Outperform | $287 |
| 2026-09-02 | Oppenheimer | Maintains | Outperform | $304 → $312 |
| 2026-09-01 | Morgan Stanley | Maintains | Overweight | $275 → $273 |
| 2026-09-01 | Wedbush | Reiterates | Outperform | $327 |
| 2026-08-31 | Bank of America | Maintains | Buy | $306 → $304 |
| 2026-08-31 | Jefferies | Maintains | Buy | $333 → $330 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-26
- neutral: RSI (14): RSI is 61 — neutral momentum, neither overbought nor oversold.
- bullish: Price vs 50-day MA: Trading 1.1% above the 50-day MA ($242.53).
- bullish: Price vs 200-day MA: Trading 3.3% above the 200-day MA ($237.32).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+3.11) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($196.01) and high ($277.18).
ASND Price Chart
Loading chart for ASND…
Fundamentals
About Ascendis Pharma A/S
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.